Amino Acids

, Volume 30, Issue 4, pp 317–332

Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use

  • E. Karnaukhova
  • Y. Ophir
  • B. Golding
Review Article

Summary.

Human alpha-1-proteinase inhibitor is a well-characterized protease inhibitor with a wide spectrum of anti-protease activity. Its major physiological role is inhibition of neutrophil elastase in the lungs, and its deficiency is associated with progressive ultimately fatal emphysema. Currently in the US, only plasma-derived human alpha-1-proteinase inhibitor is available for augmentation therapy, which appears to be insufficient to meet the anticipated clinical demand. Moreover, despite effective viral clearance steps in the manufacturing process, the potential risk of contamination with new and unknown pathogens still exists. In response, multiple efforts to develop recombinant versions of human alpha-1-proteinase inhibitor, as an alternative to the plasma-derived protein, have been reported. Over the last two decades, various systems have been used to express the human gene for alpha-1-proteinase inhibitor. This paper reviews the recombinant versions of human alpha-1-proteinase inhibitor produced in various hosts, considers current major safety and efficacy issues regarding recombinant glycoproteins as potential therapeutics, and the factors that are impeding progress in this area1.

Keywords: Alpha-1-proteinase inhibitor – Antitrypsin – Emphysema – Glycosylation – Recombinant 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abboud, RT, Ford, GT, Chapman, KR 2005Emphysema in alpha-1-antitrypsin deficiency: does replacement therapy affect outcome?Treat Respir Med418PubMedGoogle Scholar
  2. Altmann, F, Staudacher, E, Wilson, IBH, März, L 1999Insect cells as hosts for the expression of recombinant glycoproteinsGlycoconj J16109123PubMedGoogle Scholar
  3. Alviano, CS, Travassos, LR, Schauer, R 1999Sialic acids in fungi: a minireviewGlycoconj J16545554PubMedGoogle Scholar
  4. Andersen, DC, Bridges, T, Gawlitzek, M, Hoy, C 2000Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activatorBiotechnol Bioeng702531PubMedGoogle Scholar
  5. Archibald, AL, McClenaghan, M, Horsney, V, Simons, JP, Clark, AJ 1990High-level expression of biologically active human alpha-1-antitrypsin in the milk of transgenic miceProc Natl Acad Sci USA8751785182PubMedGoogle Scholar
  6. Avron, A, Reeve, FH, Lickorish, JM, Carrell, RW 1991Effect of alanine insertion (P′5) on the reactive center of alpha1-antitrypsinFEBS Lett2804143PubMedGoogle Scholar
  7. Baneyx, F 1999Recombinant protein expression in Escherichia coliCurr Opin Biotechnol10411421PubMedGoogle Scholar
  8. Barker, AF, Seimsen, F, Pasley, D, D’Silva, R, Sonia, A 1994Replacement therapy for hereditary alpha 1-antitrypsin deficiencyChest10514061410PubMedGoogle Scholar
  9. Beatty, K, Bieth, J, Travis, J 1980Kinetics of association of serine proteinases with native and oxidized α-1 proteinase inhibitor and α-1 antichymotrypsinJ Biol Chem25539313934PubMedGoogle Scholar
  10. Beljelarskaya, SN 2002A baculovirus expression system for insect cellsMol Biol36281292Google Scholar
  11. Bird, PI, Pak, SC, Worrall, DM, Bottomley, SP 2004Production of recombinant serpins in Escherichia coliMethods32169176PubMedGoogle Scholar
  12. Bischoff, R, Speck, D, Lepage, P, Delatre, L, Ledoux, C, Brown, SW, Roitsch, C 1991Purification and biochemical characterization of recombinant α1-antitrypsin variants expressed in Escherichia coliBiochemistry3034643472PubMedGoogle Scholar
  13. Bobrowicz, P, Davidson, RC, Li, H, Potgieter, TI, Nett, JH, Hamilton, SR, Stadheim, TA, Miele, RG, Bobrowicz, B, Mitchell, T, Rausch, S, Renfer, E, Wildt, S 2004Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactoseGlycobiology14757766PubMedGoogle Scholar
  14. Bollen, A, Herzog, A, Cravador, A, Herion, P, Chuchana, P, Van der Straten, A, Loriau, R, Jacobs, P, Van Elsen, A 1983Cloning and expression in E. coli of full length DNA coding for human A1ATDNA4255264CrossRefGoogle Scholar
  15. Bollen, A, Loriau, R, Herzog, A, Herion, P 1984Expression of human A1AT in E. coliFEBS Lett1666770PubMedGoogle Scholar
  16. Bottomley, SP, Stone, SR 1998Protein engineering of chimeric Serpins: an investigation into effects of the serpin scaffold and reactive centre loop lengthProtein Eng1112431247PubMedGoogle Scholar
  17. Brantly, M 1996

    a1-Antitrypsin phenotypes and genotypes

    Crystal, RG eds. Alpha-1-antitrypsin deficiencyMarcel DekkerNew York211226
    Google Scholar
  18. Brantly, M 2002α1-Antitrypsin: not just an antiprotease: extending the half-life of a natural anti-inflammatory molecule by conjugation with polyethylene glycolAm J Respir Cell Mol Biol27652654PubMedGoogle Scholar
  19. Brantly, M, Nukiwa, Y, Crystal, RG 1988Molecular basis of α1-antitrypsin deficiencyAm J Med841331PubMedGoogle Scholar
  20. Brantly, ML, Paul, LD, Miller, BH, Falk, RT, Wu, M, Crystal, RG 1988Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary sympthomsAm Rev Respir Dis138327336PubMedGoogle Scholar
  21. Brantly, ML, Wittes, JT, Hubbard, RC, Fells, GA, Crystal, RG 1991Use of highly purified α1-antitrypsin standard to establish ranges for the common normal and deficient α1-antitrypsin phenotypesChest100703708PubMedGoogle Scholar
  22. Bretthauer, RK 2003Genetic engineering of Pichia pastoris to humanize N-glycosylation of proteinsTrends Biotechnol21459462PubMedGoogle Scholar
  23. Bretthauer, RK, Castellino, FJ 1999Glycosylation of Pichia pastoris-derived proteins. ReviewBiotechnol Appl Biochem30193200PubMedGoogle Scholar
  24. Cabezon, T, De Wilde, M, Herion, P, Lorian, R, Bollen, A 1984Expression of human α1-antitrypsin cDNA in the yeast Saccharomyces cerevisiaeProc Natl Acad Sci USA8165946598PubMedGoogle Scholar
  25. Cabrita, LD, Bottomley, SP 2004How do proteins avoid becoming too stable? Biophysical studies into metastable proteinsEur Biophys J338388PubMedGoogle Scholar
  26. Cai, K, Gierman, TM, Hotta, J, Stenland, CJ, Lee, DC, Pifat, DY, Petteway, SR,Jr 2005Ensuring the biologic safety of plasma-derived therapeutic proteins. Detection, inactivation and removal of pathogensBiodrugs197996PubMedGoogle Scholar
  27. Cantin, A, Woods, DE, Cloutier, D, Heroux, J, Dufour, EK, Ledoc, R 2002aLeukocyte elastase inhibition therapy in cystic fibrosis: role of glycosylation on the distribution of alpha-1-proteinase inhibitor in blood versus lungJ Aerosol Med15141148Google Scholar
  28. Cantin, AM, Woods, DE, Cloutier, D, Dufour, EK, Leduc, R 2002bPolyethylene glycol conjugation at Cys232 prolongs the half life α1 proteinase inhibitorAm J Respir Cell Mol Biol27659665Google Scholar
  29. Carlson, JA, Rogers, BB, Sifers, RN, Hawkins, HK, Finegold, MJ, Woo, SL 1988Multiple tissues express alpha 1-antitrypsin in transgenic mice and manJ Clin Invest822636PubMedGoogle Scholar
  30. Carp, H, Miller, F, Hoidal, JR, Janoff, A 1982Potential mechanism of emphysema: α1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacityProc Natl Acad Sci USA7920412045PubMedGoogle Scholar
  31. Carrell, RW, Jeppson, JO, Vaughan, L, Brennan, SO, Owen, MC, Boswell, DR 1981Human α1-antitrypsin: carbohydrate attachment and sequence homologyFEBS Lett135301303PubMedGoogle Scholar
  32. Carrell, RW, Jeppson, JO, Laurell, CB, Brennan, SO, Owen, MC, Vaughan, L, Boswell, DR 1982Structure and variation of human α1-antitrypsin. ReviewNature298329334PubMedGoogle Scholar
  33. Carver, A, Wright, G, Cottom, D, Cooper, J, Dalrymple, M, Temperley, S, Udell, M, Reeves, D, Percy, J, Scott, A,  et al. 1992Expression of human alpha-1-antitrypsin in transgenic sheepCytotechnology97784PubMedGoogle Scholar
  34. Carver, AS, Dahymple, MA, Wright, G, Cottom, DS, Reeves, DB, Gibson, YH, Keenan, JL, Barrass, JD, Scott, AR, Colman, A, Garner, I 1993Transgenic livestock as bioreactors: Stable expression of human alpha-1-antitrypsin by a flock of sheepBio/Technology1112631270PubMedGoogle Scholar
  35. Casolaro, MA, Fells, G, Wewers, M, Pierce, JE, Ogushi, F, Hubbard, R, Sellers, S, Forstrom, J, Lyons, D, Kawasaki, G, Crystal, RG 1987J Appl Physiol6320152023PubMedGoogle Scholar
  36. Chamberlain, P 2002aImmunogenicity of therapeutic proteins. Part 1: Causes and clinical manifestations of immunogenicityRegul Rev549Google Scholar
  37. Chamberlain, P 2002bImmunogenicity of therapeutic proteins. Part 1: Measurement, prediction, minimization and regulatory consequences of immunogenicityRegul Rev5410Google Scholar
  38. Chamberlain, P, Mire-Sluis, AR 2003

    An overview of scientific and regulatory issues for the immunogenecity of biological products

    Brown, FMire-Sluis, AR eds. Immunogenecity of therapeutic biological productsKargerBasel311
    Google Scholar
  39. Chapman, AP, Antoniw, P, Spitali, M, West, S, Stephens, S, King, DJ 1999Therapeutic antibody fragments with prolonged in vivo half-livesNat Biotechnol17780783PubMedGoogle Scholar
  40. Chen, M, Liu, X, Wang, Z, Song, J, Qi, Q, Wang, PG 2005Modification of plant N-glycans processing: the future of producing therapeutic protein by transgenic plantsMed Res Rev25343360PubMedGoogle Scholar
  41. Chiba, Y, Suzuki, M, Yoshida, S, Yoshida, A, Ikenaga, H, Takeuchi, M, Jigami, Y, Ichishima, E 1998Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiaeJ Biol Chem2732629826304PubMedGoogle Scholar
  42. Cho, YL, Chae, YK, Jung, CH, Kim, MJ, Na, YR, Kim, YH, Kang, SJ, Im, H 2005The native metastability and misfolding of serine protease inhibitorsProtein Peptide Lett12477481Google Scholar
  43. Choi, B-K, Bobrowicz, P, Davidson, RC, Hamilton, SR, Kung, DH, Li, H, Miele, RG, Nett, JH, Wildt, S, Gerngross, TU 2003Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastorisProc Natl Acad Sci10050225027PubMedGoogle Scholar
  44. Chrispeels, MJ, Loic, F 1996

    The production of recombinant glycoproteins with defined nonimmunogenic glycans

    Owen, MRLPen, J eds. Transgenic plants: a production system for inductrial and pharmaceutical proteinsJ WileyNew York99113
    Google Scholar
  45. Chu, L, Robinson, DK 2001Industrial choices for protein production by large-scale cell culture. ReviewCurr Opin Biotechnol12180187PubMedGoogle Scholar
  46. Chung, BH, Kim, SJ, Kang, HA, Yu, MH 1998Secretory expression of human α1-antitrypsin in Saccharomyces cerevisiae using galactose as a gratuitous inducerBiotechnol Lett20307311Google Scholar
  47. Ciccarelli, E, Alonso, MA, Cresteli, D, Bollen, A, Jacobs, P, Alvarez, F 1993Intracellular retention and degradation of human mutant variant of a alpha 1-antitrypsin in stably transfected Chinese hamster ovary cell linesEur J Biochem213271276PubMedGoogle Scholar
  48. Cockett, MI 1999Technology evaluation: cystic fibrosis therapy, GenzymeCurr Opin Mol Ther1279283PubMedGoogle Scholar
  49. Colman, A 1996Production of proteins in the milk of transgenic livestock: problems, solutions and successesAm J Clin Nutrition63639S645SGoogle Scholar
  50. Colman, A 1999Dolly, Polly and other ‘ollys’: likely impact of cloning technology on biomedical uses of livestock. ReviewGenet Anal15167173PubMedGoogle Scholar
  51. Conesa, A, Punt, PJ, van Luijk, N, van den Hondel, CA 2001The secretion pathway in filamentous fungi: a biotechnological viewFungal Genet Biol33155171PubMedGoogle Scholar
  52. Courtney, M, Buchwalder, A, Tessier, LH, Jaye, M, Benavente, A, Balland, A, Kohli, V, Lathe, R, Tolstoshev, P, Lecocq, JP 1984High-level production of biologically active human a1-antitrypsin in Escherichia coliProc Natl Acad Sci USA81669673PubMedGoogle Scholar
  53. Courtney, M, Jallat, S, Tessier, LH, Benavente, A, Crystal, RG, Lecocq, JP 1985Synthesis in E. coli of α1-antitrypsin variants of therapeutic potential for emphysema and thrombosisNature313149151PubMedGoogle Scholar
  54. Cowden, DI, Fisher, GE, Weeks, RL 2005A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) productsCurr Med Res Opin21877883PubMedGoogle Scholar
  55. Cregg, JM, Cereghino, JL, Shi, J, Higgins, DR 2000Recombinant protein expression in Pichia pastoris. ReviewMol Biotechnol162352PubMedGoogle Scholar
  56. Cryan, SA 2005Carrier-based strategies for targeting protein and peptide drugs to the lungsAAPS J7E20E31PubMedGoogle Scholar
  57. Crystal, RG 1989The α1-antitrypsin gene and its deficiency statesTrends Genet5411417PubMedGoogle Scholar
  58. Crystal, RG, Brantly, ML, Hubbard, RC, Curiel, DT, States, DJ, Holmes, MD 1988The α1-antitrypsin gene and its mutations: clinical consequences and strategies for therapyChest95196208Google Scholar
  59. Crystal, RG 1990α1-antitrypsin deficiency, emphysema, and liver disease: Genetic basis and strategies for therapyJ Clin Invest8513431352PubMedGoogle Scholar
  60. Crystal, RG 1991Alpha1-antitrypsin deficiency: pathogenesis and treatmentHosp Pract268194Google Scholar
  61. Crystal, RG eds. 1996Alpha-1-antitrypsin deficiency. Biology – pathogenesis – clinical manifestations – therapyMarcel DekkerNew YorkGoogle Scholar
  62. Dalrymple, MA, Garner, I 1998Genetically modified livestock for the production of human proteins in milkBiotechnol Genet Eng Rev153349PubMedGoogle Scholar
  63. de Serres, FJ 2002Worldwide racial and ethnic distribution of alpha-1-antitrypsin deficiency: detailes of an analysis of published genetic epidemiological surveysChest12218181829PubMedGoogle Scholar
  64. de Serres, FJ 2003Alpha-1 Antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosedEnviron Health Perspect11118511854PubMedCrossRefGoogle Scholar
  65. Elliott, PR, Lomas, DA, Carrell, RW, Abrahams, JP 1996Inhibitory conformation of the reactive loop of α1-antitrypsinNature Struct Biol3676681PubMedGoogle Scholar
  66. Fenouillet, E, Miquelis, R, Drillien,  1996Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell linesVirology218224231PubMedGoogle Scholar
  67. Flotte, TR 2002Recombinant adeno-associated virus gene therapy for cystic fibrosis and α1-antitrypsin deficiencyChest12198S102SPubMedGoogle Scholar
  68. Fukuda, M 2000

    Cell surface carbohydrates: cell type-specific expression

    Fukuda, MHindgaul, O eds. Molecular and cellular glycobiologyOxford University PressNew York1261
    Google Scholar
  69. Garcia-Contereras, L, Hickey, AJ 2003Aerosol treatment of cystic fibrosisCrit Rev Ther Drug Carrier Syst20317356Google Scholar
  70. Garver, RI,Jr, Chytil, A, Karlsson, S, Fells, GA, Brantly, ML, Courtney, M, Kantoff, PW, Nienhuis, AW, Anderson, WF, Crystal, RG 1987Production of glycosylated physiologically “normal” human α1-antitrypsin by mouse fibroblasts modified by insertion of a human α1-antitrypsin cDNA using a retroviral vectorProc Natl Acad Sci USA8410501054PubMedGoogle Scholar
  71. Gerngross, TU 2004Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. ReviewNature Biotechnol2214091414Google Scholar
  72. Goebel, FD, Mannhalter, JW, Belshe, RB, Eibl, MM, Grob, PJ, de Gruttola, V, Griffiths, PD, Erfle, VV, Kunschak, M, Eng, W 1999Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trialAIDS1314611468PubMedGoogle Scholar
  73. Gomond, V, Faye, L 2004Posttranslational modification of therapeutic proteins in plantsCurr Opin Plant Biol7171181Google Scholar
  74. Gouka, RJ, Punt, PJ, van den Hondel, CA 1997Efficient production of secreted proteins by Aspergillus: progress, limitations and prospects. MinireviewAppl Microbiol Biotechnol47111PubMedGoogle Scholar
  75. Grabenhorst, E, Schlenke, P, Pohl, S, Nimtz, M, Conradt, HS 1999Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cellsGlycoconj J168197PubMedGoogle Scholar
  76. Griffith, SW, Cooney, CL 2002aDevelopment of a peptide mapping procedure to identify and quantify methionine oxidation in recombinant human alpha1-antitrypsinJ Chromatogr A942133143Google Scholar
  77. Griffiths, SW, Cooney, CL 2002bRelationship between protein structure and methionine oxidation in recombinant human alpha 1-antitrypsinBiochemistry4162456252Google Scholar
  78. Griffiths, SW, King, J, Cooney, CL 2002cThe reactivity and oxidation pathway of cysteine 232 in recombinant human alpha 1-antitrypsinJ Biol Chem2772548625492Google Scholar
  79. Harris, DP, Andrews, AT, Wright, G, Pyle, DL, Asenjo, JA 1997The application of aqueous two-phase systems to the purification of pharmaceutical proteins from transgenic sheep milkBioseparation73137PubMedGoogle Scholar
  80. Harris, JM, Martin, NE, Modi, M 2001Pegylation: a novel process for modifying pharmacokineticsClin Pharmacokinet40539551PubMedGoogle Scholar
  81. Hellwig, S, Drossard, J, Twyman, RM, Rainer Fischer, R 2004Plant cell cultures for the production of recombinant proteinsNature Biotechnol2214151422Google Scholar
  82. Hercz, A 1985Proteolytic cleavages in α1-antitrypsin and microheterogeneityBiochem Biophys Res Commun128199203PubMedGoogle Scholar
  83. Hollister, J, Grabenhorst, E, Nimtz, M, Conradt, H, Jarvis, DL 2002Engineering the protein N-glycosylation pathway in insect cells for production of biantennary, complex N-glycansBiochemistry411509315104PubMedGoogle Scholar
  84. Hopkins, PC, Carrell, RW, Stone, SR 1993Effects of mutations in the hinge region of serpinsBiochemistry3276507657PubMedGoogle Scholar
  85. Huang, J, Sutliff, TD, Wu, L, Nandi, S, Benge, K, Terashima, M, Ralston, AH, Drohan, W, Huang, N, Rodriguez, RL 2001Expression and purification of functional human α-1-antitrypsin from cultured plant cellsBiotechnol Prog17126133PubMedGoogle Scholar
  86. Hubbard, RC, Crystal, RG 1990Strategies for aerosol therapy of alpha1-antitrypsin deficiency by the aerosol routeLung168565578PubMedGoogle Scholar
  87. Hubbard, RC, Brantly, MI, Sellers, SE, Mitchell, ME, Crystal, RG 1989Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsinAnn Intern Med111206212PubMedGoogle Scholar
  88. Huntington, JA, Read, RJ, Carrell, RW 2000Structure of a serpin-protease complex shows inhibition by deformationNature407923926PubMedGoogle Scholar
  89. Hutchison, DSC, Hughes, MD 1997Alpha(1)-antitrypsin replacement therapy: will efficacy ever be proved?Eur Resp J1021922193Google Scholar
  90. Im, H, Seo, EI, Yu, MH 1999Metastability in the inhibitory mechanism of human alpha1-antitrypsinJ Biol Chem2741107211077PubMedGoogle Scholar
  91. Im, H, Woo, MS, Hwang, KY, Yu, MH 2002Interactions causing the kinetic trap in serpin protein foldingJ Biol Chem2774634746354PubMedGoogle Scholar
  92. Im, H, Ryu, MJ, Yu, MH 2004Engineering thermostability in serine protease inhibitorsProtein Eng Des Select17325331Google Scholar
  93. Janciauskiene, S, Larsson, S, Larsson, P, Virtala, R, Jansson, L, Stevens, T 2004Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsinBiochem Biophys Res Commun321592600PubMedGoogle Scholar
  94. Jayakumar, A, Cataltepe, S, Kang, Y, Frederick, MJ, Mitsudo, K, Henderson, Y, Crawford, SE, Silverman, GA, Clayman, GL 2004Production of serpins using baculovirus expression systemsMethods32177184PubMedGoogle Scholar
  95. Johansen, H, Sutiphong, J, Sathe, G, Jacobs, P, Cravador, A, Bollen, A, Rosenberg, M, Shatzman, A 1987High-level production of fully active human alpha 1-antitrypsin in Escherichia coliMol Biol Med4291305PubMedGoogle Scholar
  96. Johnson, D, Travis, J 1977Inactivation of human α1-proteinase inhibitor by thiol proteinasesBiochem J163639664PubMedGoogle Scholar
  97. Johnson, D, Travis, J 1979The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive centerJ Biol Chem25440224026PubMedGoogle Scholar
  98. Juvelekian, GS, Stoller, JK 2004Augmentation therapy for α1-antitrypsin deficiencyDrugs6417431756PubMedGoogle Scholar
  99. Kang, HA, Nam, SW, Kwon, K-S, Chung, BH, Yu, M-H 1996High level secretion of human α1-antitrypsin from Saccharomyces cerevisiae using inulinase signal sequenceJ Biotechnol481524PubMedGoogle Scholar
  100. Kang, HA, Sohn, JH, Choi, ES, Chung, BH, Yu, M-H, Rhee, SK 1998Glycosylation of human α1-antitrypsin in Saccharomyces cerevisiae and methylotrophic yeastsYeast14371381PubMedGoogle Scholar
  101. Karnaukhova E, Ophir Y, Golding B, Shrake A (2004) Recombinant human alpha-1-proteinase inhibitor: glycosylation, stability and biological activity. Abstract of 10th FDA Science Forum: The critical path from concept to consumer. B-18, p 47. Washington DC, May 18–19, 2004Google Scholar
  102. Karnaukhova, E, Ophir, Y, Trinh, L, Shrake, A, Golding, B, Punt, PJ, Shiloach, J 2005Recombinant human alpha-1-proteinase inhibitor. Expression in Aspergillus nigerAmino Acids2951Google Scholar
  103. Kim, J, Lee, KN, Yi, GS, Yu, MH 1995A thermostable mutation located at the hydrophobic core of α1-antitrypsin suppresses the folding defect of the Z-type variantJ Biol Chem27085978601PubMedGoogle Scholar
  104. Krasnewich, DM, Holt, GD, Brantly, M, Skovby, F, Redwine, J, Gahl, WA 1995Abnormal synthesis of dolichol-linked oligosaccharides in carbohydrate-deficient glycoprotein syndromeGlycobiology5503510PubMedGoogle Scholar
  105. Kropp, J, Wencker, M, Hotze, A, Banik, N, Hübner, GE, Wunderlich, G, Ulbrich, E, Konietzko, N, Biersack, HJ 2001Inhalation of [123I]α1-protease inhibitor: toward a new therapeutic concept of α1-protease inhibitor deficiency?J Nucleic Med42744751Google Scholar
  106. Kwon, K-S, Song, M, Yu, MH 1995Purification and characterization of α1-antitrypsin secreted by recombinant yeast Saccharomyces diastaticusJ Biotechnol42191195PubMedGoogle Scholar
  107. Kwon, KS, Kim, J, Shin, HS, Yu, MH 1994Single amino acid substitutions of a1- antitrypsin that confer enhancement in thermal stabilityJ Biol Chem26996279631PubMedGoogle Scholar
  108. Lee, KN, Park, SD, Yu, MH 1996Probing the native strain in a1-antitrypsinNature Struct Biol3497500PubMedGoogle Scholar
  109. Lee, C, Park, SH, Lee, MY, Yu, MH 2000Regulation of protein function by native metastabilityProc Natl Acad Sci USA977277731Google Scholar
  110. Levine, RL, Berlett, BS, Moskovitz, J, Mosoni, L, Stadtman, ER 1999Methionine residues may protect proteins from critical oxidative damageMech Ageing Dev107323332PubMedGoogle Scholar
  111. Levine, RL, Moskovitz, J, Stadtman, ER 2000Oxidation of methionine in proteins: roles in antioxidant defense and cellular regulationIUBMB Life50301307PubMedGoogle Scholar
  112. Loebermann, H, Tokuoki, R, Deisenhofer, J, Huber, R 1984Human α-1 proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for functionJ Mol Biol177531556PubMedGoogle Scholar
  113. Lomas, DA, Finch, JT, Seyama, K, Nukiwa, T, Carrell, RW 1993α1-antitrypsin Siiyama (Ser53→Phe). Further evidence for intracellular loop-sheet polymerisationJ Biol Chem2681533315335PubMedGoogle Scholar
  114. Lomas, DA, Elliott, PR, Chang, W-SW, Wardell, MR, Carrell, RW 1995Preparation and characterization of latent α1-antitrypsinJ Biol Chem27052825288PubMedGoogle Scholar
  115. Lomas, DA, Elliott, PR, Carrell, RW 1997Commercial plasma α1-antitrypsin (Prolastin®) contains a conformationally inactive, latent componentEur Respir J10672675PubMedGoogle Scholar
  116. Lomas, D 2005Molecular mousetraps, α1-antitrypsin deficiency and the serpinopathiesClin Med5249257PubMedGoogle Scholar
  117. Long, GL, Chandra, T, Woo, SLC, Davie, EW, Kurachi, K 1984Complete sequence of the cDNA for human α1-antitrypsin and the gene for the S variantBiochemistry2348284837PubMedGoogle Scholar
  118. Lubon, H, Palmer, C 2000Transgenic animal bioreactors – where we areTransgenic Res9301304Google Scholar
  119. Luckow, VA 1993Baculovirus systems for the expression of human gene productsCurr Opin Biotechnol4564572PubMedGoogle Scholar
  120. Ludeman, JP, Whisstock, JC, Hopkins, PCR, Le Bonniec, BF, Bottomley, SP 2001Structure of a serpin-enzyme complex probed by cysteine substitutions and fluorescence spectroscopyBiophys J80491497PubMedCrossRefGoogle Scholar
  121. Luisetti, M, Seersholm, N 2004Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiencyThorax59164169PubMedGoogle Scholar
  122. Lupi, A, Viglio, S, Luisetti, M, Gorrini, M, Coni, P, Faa, G, Cetta, G, Iadarola, P 2000α1-Antitrypsin in serum determined by capillary isoelectric focusingElectrophoresis2133183326PubMedGoogle Scholar
  123. Macauley-Patrick, S, Fazenda, ML, McNeil, B, Harvey, LM 2005Heterologous protein production using the Pichia pastoris expression system. ReviewYeast22249270PubMedGoogle Scholar
  124. Macmillan, D, Betozzi, CR 2000New directions in glycoprotein engineeringTetrahedron5695159525Google Scholar
  125. Maras, M, van Die, I, Contreras, R, van den Hondel, CA 1999Filamentous fungi as production organisms for glycoproteins of bio-medical interestGlycoconj J1699107PubMedGoogle Scholar
  126. Marchal, I, Jarvis, DL, Cacan, R, Verbert, A 2001Glycoproteins from insect cells: sialylated or not?Biol Chem382151159PubMedGoogle Scholar
  127. Massoud, M, Bischoff, R, Dalemans, W, Pointu, H, Attal, J, Schultz, H, Clesse, D, Stinnakre, MG, Pavirani, A, Houdebine, LM 1991Expression of active recombinant human alpha 1-antitrypsin in transgenic rabbitsJ Biotechnol18193203PubMedGoogle Scholar
  128. Mast, AE, Salvesen, G, Schnebli, HP, Pizzo, SV 1990aEvaluation of the rapid plasma elimination of recombinant α1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potentialJ Lab Clin Invest1165865Google Scholar
  129. Mast, AE, Salvesen, G, Brucato, FH, Schnebli, HP, Pizzo, SV 1990bPolyethylene glycol modification of serpins improves therapeutic potentialBiol Chem Hoppe Seyler371101109Google Scholar
  130. McElvaney, NG, Hubbard, RC, Birrer, P, Chernick, MS, Caplan, DB, Frank, MM, Crystal, RG 1991Aerosol alpha 1-antitrypsin treatment for cystic fibrosisLancet337392394PubMedGoogle Scholar
  131. Mega, T, Lujan, E, Yoshida, A 1980aStudies on the oligosaccharade chains of human α1-protease inhibitor: I. Isolation of glycopeptidesJ Biol Chem25540534056Google Scholar
  132. Mega, T, Lujan, E, Yoshida, A 1980bStudies on the oligosaccharade chains of human α1-protease inhibitor: II. Structure of oligosaccharidesJ Biol Chem25540574061Google Scholar
  133. Monfardini, C, Veronese, FM 1998Stabilization of substances in circulationBioconjugate Chem9418450Google Scholar
  134. Morrow, T 2004Despite challenges, new treatments around for AAT deficiencyManag Care134849Google Scholar
  135. Needham, M, Stockley, RA 2004Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural historyThorax59441445PubMedGoogle Scholar
  136. Nevalainen, KMH, Valentino, SJT, Bergquist, PL 2005Heterologous protein expression in filamentous fungiTrends Biotechnol23468474PubMedGoogle Scholar
  137. Nightingale SD (1998) Summary of the Advisory Committee on Blood Safety and Availability Meeting on April 27 and 28,1998. Washington, D.C.: Department of Health and Human Services. (http://www.hhs.gov/bloodsafety/summaries/sumapr98.html)
  138. Nita, I, Hollander, C, Westin, U, Janciauskiene, SM 2005Prolastin, a pharmaceutical preparation of purified human α1-antitrypsin, blocks endotoxin-mediated cytokine releaseResp Res61223Google Scholar
  139. Novoradovskaya, N, Lee, JH, Yu, ZX, Ferrans, VJ, Brantly, M 1998Inhibition of intracellular degradation increases secretion of a mutant form of α1-antitrypsin associated with profound deficiencyJ Clin Invest10126932701PubMedGoogle Scholar
  140. O’Reilly, DR, Miller, LK, Luckow, VA 1994Baculovirus expression vectors: a laboratory manual2Oxford University PressNew YorkGoogle Scholar
  141. Paakko, P, Kirby, M, du Bois, RM, Gillissen, A, Ferrans, VJ, Crystal, RG 1996Activated neutrophils secrete stored α1-antitrypsinAm J Respir Crit Care Med15418291833PubMedGoogle Scholar
  142. Paterson, T, Innes, J, Moore, S 1994Approaches to maximizing stable expression of α1-antitrypsin in transformed CHO cellsAppl Microbiol Biotechnol40691698PubMedGoogle Scholar
  143. Pavirani, A, Skern, T, Le Meur, M, Lutz, Y, Lathe, R, Crystal, RG, Fuchs, JP, Gerlinger, P, Courtney, M 1989Recombinant proteins of therapeutic interest expressed by lymphoid cell lines derived from transgenic miceBiotechnology710491054Google Scholar
  144. Pemberton, PA, Bird, PI 2004Production of serpins using yeast expression systemsMethods32185190PubMedGoogle Scholar
  145. Punt, PJ, van Biezen, N, Conesa, A, Albers, A, Mangnus, J, van den Hondel, C 2002Filamentous fungi as cell factories for heterologous protein productionTrends Biotechnol20200206PubMedGoogle Scholar
  146. Rabin, M, Watson, M, Kidd, V, Woo, SLC, Ruddle, FH 1986Regional location of α1-antichymotrypsin and α1-antitrypsin genes on human chromosome 14Somatic Cell Mol Gen12209214Google Scholar
  147. Rosenberg, S, Barr, PJ, Najarian, RC, Hallewell, RA 1984Synthesis in yeast of a functional oxidation-resistant mutant of human α1-antitrypsinNature3127780PubMedGoogle Scholar
  148. Ryckaert, S, Martens, V, De Vusser, K, Contreras, R 2005Development of a S. cerevisiae whole cell biocatalyst for in vitro sialylation of oligosaccharidesJ Biotechnol119379388PubMedGoogle Scholar
  149. Ryu, SE, Choi, HJ, Kwon, KS, Lee, KN, Yu, MH 1996The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved α1-antitrypsin at 2.7 ÅStructure411811192PubMedGoogle Scholar
  150. Sandhaus, RA 2004α1-Antitrypsin deficiency. 6: New and emerging treatments for α1-antitrypsin deficiencyThorax59904909PubMedGoogle Scholar
  151. Sandoval, C, Curtis, H, Congote, LF 2002Enhanced proliferation effects of a baculovirus-produced fusion protein of insulin-like growth factor and α1-proteinase inhibitor and improved anti-elastase activity of the inhibitor with glutamate in position 351Protein Eng15413418PubMedGoogle Scholar
  152. Seersholm, N, Wencker, M, Banik, N, Viskum, K, Dirksen, A, Kok-Jensen, A, Konietzko, N 1997Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary α1-antitrypsin deficiency?Eur Respir J1022602263PubMedGoogle Scholar
  153. Sidhar, SK, Lomas, DA, Carrell, RW, Foreman, RC 1995Mutations which impede loop/sheet polymerization enhance the secretion of human alpha1-antitrypsin deficiency variantsJ Biol Chem27083938396PubMedGoogle Scholar
  154. Sifers, RN, Carlson, JA, Clift, SM, DeMayo, FJ, Bullock, DW, Woo, SL 1987Tissue specific expression of the human alpha-1-antitrypsin gene in transgenic miceNucleic Acids Res1514591475PubMedGoogle Scholar
  155. Silverman, GA, Bird, PI, Carrell, RW, Church, FC, Coughlin, PB, Gettins, PGW, Irving, JA, Lomas, DA, Luke, CJ, Moyer, RW, Pemberton, PA, Remold-O’Donnell, E, Salvesen, GS, Travis, J, Whisstock, JC 2001The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclatureJ Biol Chem2763329333296PubMedGoogle Scholar
  156. Simons, JP, McClenaghan, M, Clark, AJ 1987Alteration of the quality of milk by expression of sheep beta-lactoglobulin in transgenic miceNature328530532PubMedGoogle Scholar
  157. Smith, RM, Traber, LD, Traber, DL, Spragg, RG 1989Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheepJ Clin Invest8411451154PubMedCrossRefGoogle Scholar
  158. Snider GL (1992) Emphysema: the first two centuries and beyond: a historical overview, with suggestions for future research. Am Rev Respir Dis 146: 1334–1344 & 1615–1622Google Scholar
  159. Song, HK, Lee, KN, Kwon, KS, Yu, MH, Suh, SW 1995Crystal structure of an uncleaved α1-antitrypsin reveals the conformation of its inhibitory reactive loopFEBS Lett377150154PubMedGoogle Scholar
  160. Spencer, LT, Humphries, JE, Brantly, ML 2005Antibody response to aerosolized transgenic human alpha1-antitrypsinN Engl J Med35220302031PubMedGoogle Scholar
  161. Stecenko, AA, Brigham, KL 2003Gene therapy progress and prospects: alpha-1 antitrypsin. ReviewGene Ther109599PubMedGoogle Scholar
  162. Stein, PE, Carrell, RW 1995What do dysfunctional serpins tell us about molecular mobility and disease?Nat Struct Biol296113PubMedGoogle Scholar
  163. Stockley, RA 2000Apha-1-antitrypsin deficiency: what next?Thorax55614618PubMedGoogle Scholar
  164. Stockley, RA, Bayley, DL, Unsal, I, Dowson, LJ 2002The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiencyAm J Respir Crit Care Med16514941498PubMedGoogle Scholar
  165. Stratikos, E, Gettins, PGW 1997Major proteinase movement upon stable serpin-proteinase complex formationProc Natl Acad Sci USA94453458PubMedGoogle Scholar
  166. Stratikos, E, Gettins, PGW 1998Mapping the serpin-proteinase complex using single cysteine variants of α1-antitrypsin inhibitor PittsburghJ Biol Chem2731558215589PubMedGoogle Scholar
  167. Stratikos, E, Gettins, PGW 1999Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive centre loop into β-sheet AProc Natl Acad Sci USA9648084813PubMedGoogle Scholar
  168. Straus, SD, Fells, GA, Wewers, MD, Courtney, M, Tessier, LH, Tolstoshev, P, Lecocq, JP, Crystal, RG 1985Evaluation of recombinant DNA-directed E.coli produced alpha 1-antitrypsin as an anti-neutrophil elastase for potential use as replacement therapy of alpha 1-antitrypsin deficiencyBiochem Biophys Res Commun13011771184PubMedGoogle Scholar
  169. Sutiphong, J, Johansen, H, Sathe, G, Rosenberg, GS, Shatzman, A 1987Selection of mutations that increase alpha 1-antitrypsin gene expression in Escherichia coliMol Biol Med4307322PubMedGoogle Scholar
  170. Swartz, JR 2001Advances in Escherichia coli production of therapeutic proteinsCurr Opin Biotechnol12195201PubMedGoogle Scholar
  171. Taggart, C, Cervantes-Laurean, D, Kim, G, McElvaney, NG, Wehr, N, Moss, J, Levine, RL 2000Oxidation of either methionine 351 or methionine 358 in α1-antitrypsin causes loss of anti-neutrophil elastase activityJ Biol Chem2752725827265PubMedGoogle Scholar
  172. Tamer, IM, Chisti, Y 2001Production and recovery of recombinant protease inhibitor α1-antitrypsinEnzyme Microb Technol29611620Google Scholar
  173. Taylor, G, Gumbleton, M 2004Aerosols for macromolecular delivery: design challenges and solutionsAm J Drug Delivery2143155Google Scholar
  174. Tebbutt, SJ 2000Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL therapeuticsCurr Opin Mol Ther2199204PubMedGoogle Scholar
  175. Terashima, M, Murai, Y, Kawamura, M, Nakanishi, S, Stoltz, T, Chen, L, Drohan, W, Rodriguez, RL, Katoh, S 1999Production of functional human α1-antitrypsin by plant-cell cultureAppl Microbiol Biotechnol52516523PubMedGoogle Scholar
  176. Terashima, M, Ejiri, Y, Hashikawa, N, Yoshida, H 2000Effects of sugar concentration on recombinant human α1-antitrypsin production by genetically engineered rice cellBiochem Eng J6201205PubMedGoogle Scholar
  177. Travis, J, Salvesen, GS 1983Human plasma proteinase inhibitorsAnnu Rev Biochem52655709PubMedGoogle Scholar
  178. Travis, J, Owen, M, George, P, Carrell, R, Rosenberg, S, Hallewell, RA, Barr, PJ 1985Isolation and properties of recombinant DNA produced variants of human al-proteinase inhibitorJ Biol Chem26043844389PubMedGoogle Scholar
  179. Travis, J 1988Structure, function, and control of neutrophil proteinasesAm J Med843743PubMedGoogle Scholar
  180. Tsymbalenko, NV, Golinski, GF, Gaitskhoki, VS 1995Expression of the human alpha-1-antitrypsin gene in transgenic ratsBull Eksp Biol Med1208183Google Scholar
  181. US FDA Guidances: (a) Points to Consider in the Production and Testing of New Drugs and Biologicals Produced by Recombinant DNA Technology – 4/10/1985; (b) Supplement to the Points to Consider in the Production and Testing of New Drugs and Biologics Produced by Recombinant DNA Technology: Nucleic Acid Characterization and Genetic Stability – 4/6/1992; (c) Points to Consider in the Manufacture and Testing of Therapeutic Products for Human Use Derived from Transgenic Animals – 8/22/1995Google Scholar
  182. Vaughan, L 1982α1-Antitrypsin microheterogeneity: isolation and physiological significance of isoformsBiochem Biophys Acta701339345PubMedGoogle Scholar
  183. Vemuri, S, Yu, CT, Roosdorp, N 1993Formulation and stability of recombinant alpha 1-antitrypsinPharm Biotechnol5263286PubMedGoogle Scholar
  184. Vervecken, W, Kaigorodov, V, Callewaert, N, Geysens, S, De Vusser, K, Contreras, R 2004In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia pastorisAppl Envir Microbiol7026392646Google Scholar
  185. Vogelmeier, C, Kirlath, I, Warrington, S, Banik, N, Ulbrich, E, du Bois, RM 1997The intrapulmonary half-life and safety of aerosolized α1-protease inhibitor in normal volunteersAm J Respir Crit Care Med155536541PubMedGoogle Scholar
  186. Wasylnka, JA, Simmer, MI, Moore, MM 2001Differences in sialic acid density in pathogenic and non-pathogenic Aspergillus speciesMicrobiology147869877PubMedGoogle Scholar
  187. Ward, M, Victoria, DC, Fox, BP, Fox, JA, Wong, DL, Meerman, HJ, Pucci, JP, Fong, RB, Heng, MH, Tsurushita, N, Gieswein, C, Park, M, Wang, H 2004Characterization of humanized antibodies secreted by Aspergillus nigerAppl Environ Microbiol7025672576PubMedGoogle Scholar
  188. White, R, Lee, D, Habicht, GS, Janoff, A 1981Secretion of alpha-1-proteinase inhibitor by cultured rat alveolar macrophagesAm Rev Respir Dis123447450PubMedGoogle Scholar
  189. Wencker, M, Banik, N, Buhl, R, Seidel, R, Konietzko, N 1998Long-term treatment of α1-antitrypsin deficiency-related pulmonary emphysema with human α1-antitrypsinEur Respir J11428433PubMedGoogle Scholar
  190. Wilczynska, M, Fa, M, Karolin, J, Ohlsson, PI, Johansson, LB, Ny, T 1997Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpinsNat Struct Biol4354357PubMedGoogle Scholar
  191. Wildt, S, Gerngross, TU 2005The humanization of N-glycosylation pathways in yeastNat Rev Microbiol3119128PubMedGoogle Scholar
  192. Withers, JM, Swift, RJ, Wiebe, MG, Robson, GD, Punt, PJ, van den Hondel, CA, Trinci, AP 1998Optimization and stability of glucoamylase production by recombinant strains of Aspergillus niger in chemostat cultureBiotechnol Bioeng59407418PubMedGoogle Scholar
  193. WHO (1997) World Health Organization, Human Genetics Programme. Alpha-1-antitrypsin deficiency. Report of WHO meeting 75: 397–415. Geneva, 18–20 March, 1996Google Scholar
  194. Wright, G, Carver, A, Cottom, D, Reeves, D, Scott, A, Simons, P, Wilmut, I, Gamer, J, Colman, A 1991High level of expression of active human alpha-1-antitrypsin in the milk of transgenic sheepBio/Technology9830834PubMedGoogle Scholar
  195. Yu, C, Roosdorp, N, Pushpala, S 1988Physical stability of a recombinant alpha 1-antitrypsin injectionPharm Res5800802PubMedGoogle Scholar
  196. Zbikowska, HM, Soukhareva, N, Behnam, R, Lubon, H, Hammond, D, Soukharev, S 2002Uromodulin promoter directs high-level expression of biologically active human α1-antitrypsin into mouse urineBiochem J365711PubMedGoogle Scholar
  197. Zhou, A, Carrell, RW, Hungtington, JA 2001The Serpin inhibitory mechanism is critically dependent on the length of the reactive center loopJ Biol Chem2762754127547PubMedGoogle Scholar
  198. Ziomek, CA 1998Commercialization of proteins produced in the mammary glandTheriogenology49139144PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • E. Karnaukhova
    • 1
  • Y. Ophir
    • 1
  • B. Golding
    • 1
  1. 1.Division of HematologyCenter for Biologics Evaluation and Research, Food and Drug AdministrationBethesdaU.S.A.

Personalised recommendations